Tracking treatment evolution in metastatic breast cancer since 2008
Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Database: Evolution of the Therapeutic Care in Metastatic Breast Cancer Across the French Comprehensive Cancer Centers From 2008
This study looks at how treatment for metastatic breast cancer has changed since 2008 by gathering and analyzing patient information from 18 cancer centers in France.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Unicancer Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 20 sites (Angers and 19 other locations) |
| Trial ID | NCT03275311 on ClinicalTrials.gov |
What this trial studies
This observational study utilizes a multicenter database to collect retrospective data from electronic medical records of patients with metastatic breast cancer across 18 comprehensive cancer centers in France. The ESME Breast cancer Database compiles detailed information on patient demographics, tumor characteristics, treatment protocols, and clinical events. Data is collected by trained technicians using an electronic data collection tool, ensuring that all information is harmonized and anonymized before analysis. The study aims to analyze treatment strategies and outcomes for patients treated since January 2008.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with metastatic breast cancer who have received treatment at a participating French comprehensive cancer center.
Not a fit: Patients who do not have metastatic breast cancer or who have not received treatment at one of the participating centers may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of various treatment strategies for metastatic breast cancer, potentially improving patient care.
How similar studies have performed: Other studies utilizing real-world data in similar contexts have shown success in understanding treatment outcomes, making this approach both relevant and promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria : * 18 years old patient * Patient receiving chemotherapy, targeted therapy, immunotherapy, radiation therapy and hormonotherapy in a French Comprehensive Cancer Center. Exclusion criteria : None
Where this trial is running
Angers and 19 other locations
- Institut de Cancérologie de l'Ouest - Paul Papin — Angers, France (Recruiting)
- Institut Bergonié — Bordeaux, France (Recruiting)
- Centre François Baclesse — Caen, France (Recruiting)
- Centre Jean Perrin — Clermont-Ferrand, France (Recruiting)
- Centre Georges-François Leclerc — Dijon, France (Recruiting)
- Centre Oscar Lambret — Lille, France (Recruiting)
- Centre Léon Bérard — Lyon, France (Recruiting)
- Institut Paoli-Calmettes — Marseille, France (Recruiting)
- Institut régional du Cancer Montpellier / Val d'Aurelle — Montpellier, France (Recruiting)
- Institut de Cancérologie de Lorraine — Nancy, France (Recruiting)
- Institut de cancérologie de l'Ouest - René Gauducheau — Nantes, France (Recruiting)
- Centre Antoine Lacassagne — Nice, France (Recruiting)
- Institut Curie — Paris, France (Recruiting)
- Institut Jean Godinot — Reims, France (Recruiting)
- Centre Eugène Marquis — Rennes, France (Recruiting)
- Centre Henri Becquerel — Rouen, France (Recruiting)
- Institut Curie - Hôpital René Huguenin — Saint-Cloud, France (Recruiting)
- Centre Paul Strauss — Strasbourg, France (Recruiting)
- Institut Claudius Regaud — Toulouse, France (Recruiting)
- Institut Gustave Roussy — Villejuif, France (Recruiting)
Study contacts
- Study coordinator: Lise Bosquet, MsC
- Email: l-bosquet@unicancer.fr
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.